Think Bioscience Lands $55M Series A, Spotlighted in Biotech Venture Capital Tracker

Think Bioscience, a biotechnology company based in Boulder, Colorado, has raised $55 million in a Series A funding round to accelerate the development of small-molecule therapies targeting proteins traditionally considered “undruggable.” The financing, led by a consortium of venture investors in the United States, will support expansion of the company’s synthetic biology platform and the advancement of programs focused on rare genetic disorders. This funding reflects growing investor interest in innovative approaches that address complex and unmet medical needs.

Series A to Expand Pipeline and Accelerate Synthetic Biology Platform

The Series A round attracted participation from several prominent investors, including Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, along with previous backers returning to support the company. The level of investment, which exceeded the initial target, indicates strong confidence in Think Bioscience’s scientific strategy and operational potential.

Think Bioscience plans to use the new capital to expand its internal pipeline, particularly programs aimed at rare diseases, while enhancing its proprietary discovery platform. This platform leverages microbial systems to reveal protein binding sites that are often inaccessible using conventional drug design methods. By enabling the design of small molecules that can interact with these challenging targets, the platform opens possibilities for treatments that were previously out of reach.

Investors have highlighted the innovative nature of the company’s approach. By applying synthetic biology techniques, Think Bioscience can identify “hidden” interaction points on proteins, allowing researchers to explore therapeutic strategies that traditional chemistry has struggled to achieve. The company’s lead program is focused on Noonan syndrome, a rare genetic condition affecting cardiac, lymphatic, and developmental functions. With no approved therapies directly targeting its underlying cause, this program represents a high-priority area for clinical research.

Biotech Investment Trends Highlight Demand for Innovative Therapies

The Series A comes at a time when venture investment in biotech has been adjusting to a more selective market. While overall financing activity has slowed compared with peak years, investors remain drawn to startups tackling high-value scientific challenges with innovative technologies. Companies offering novel discovery platforms, particularly in synthetic biology and protein-targeted drug development, are attracting attention due to their potential to expand therapeutic possibilities.

Think Bioscience’s trajectory also highlights the importance of academic research in fueling biotech innovation. The company originated from work conducted at the University of Colorado Boulder, where its discovery platform was initially developed. This transition from university research to a commercial biotech venture underscores the role of foundational science in driving new treatments and attracting venture capital.

The $55 million Series A provides Think Bioscience with the resources to advance its internal pipeline and further develop its synthetic biology platform. The company aims to create therapies for rare and traditionally “undruggable” proteins, potentially opening new treatment options where few exist. This funding milestone highlights investor confidence in the company’s innovative approach and its potential to address critical gaps in medical research.